{"id":"anti-cd20-antibody","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infusion reactions"},{"rate":"10-20","effect":"Infections"},{"rate":"5-15","effect":"Cytopenias"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CD20 is a surface antigen expressed on B lymphocytes from the pre-B cell stage through mature B cells but absent on hematopoietic stem cells and plasma cells. By targeting CD20, these antibodies selectively eliminate B cells, reducing autoimmune responses and abnormal B cell proliferation. This mechanism is effective in both B-cell malignancies and autoimmune diseases where B cells play a pathogenic role.","oneSentence":"Anti-CD20 antibodies bind to CD20 antigen on B cells, leading to B cell depletion through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:12.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Chronic lymphocytic leukemia"},{"name":"Autoimmune diseases (e.g., rheumatoid arthritis, pemphigus vulgaris)"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT04840602","phase":"PHASE2","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-01-05","conditions":"Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia","enrollment":92},{"nctId":"NCT05131022","phase":"PHASE1","title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2022-04-13","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":572},{"nctId":"NCT01886872","phase":"PHASE3","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-15","conditions":"Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia","enrollment":547},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT02160015","phase":"PHASE1","title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-20","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT06015880","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-20","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT03701282","phase":"PHASE3","title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":720},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT04269902","phase":"PHASE3","title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-02","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":247},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":120},{"nctId":"NCT06337318","phase":"PHASE3","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-10-23","conditions":"Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features","enrollment":600},{"nctId":"NCT03737981","phase":"PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":465},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT01695941","phase":"PHASE1","title":"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-31","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT01829568","phase":"PHASE1","title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-26","conditions":"Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","enrollment":33},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT07491900","phase":"PHASE1","title":"A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)","status":"RECRUITING","sponsor":"Hinge Bio","startDate":"2026-03-23","conditions":"Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Extra-renal Lupus (ERL)","enrollment":30},{"nctId":"NCT01842386","phase":"PHASE1","title":"Rituximab for Anti-cytokine Autoantibody-Associated Diseases","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-04-29","conditions":"Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis","enrollment":7},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06149286","phase":"PHASE3","title":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-28","conditions":"Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)","enrollment":470},{"nctId":"NCT07003295","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-14","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT04095156","phase":"","title":"Autoreactive B Cells in Membranous Nephropathy","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2019-09-25","conditions":"Membranous Nephropathy","enrollment":86},{"nctId":"NCT05025800","phase":"PHASE1, PHASE2","title":"ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-13","conditions":"Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":47},{"nctId":"NCT04830137","phase":"PHASE1","title":"A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-05-05","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM)","enrollment":248},{"nctId":"NCT04458610","phase":"PHASE2","title":"Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-26","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT06943872","phase":"PHASE3","title":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-06-11","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":630},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":65},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT05783596","phase":"PHASE2","title":"Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2023-07-18","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":47},{"nctId":"NCT06572618","phase":"PHASE2","title":"Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-22","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT07218510","phase":"PHASE2","title":"Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-07","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":33},{"nctId":"NCT06784726","phase":"PHASE2","title":"Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-09-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT06442475","phase":"PHASE2","title":"Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-08-29","conditions":"Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma","enrollment":20},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT06510309","phase":"PHASE2","title":"Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2026-02-11","conditions":"Lymphoma, Marginal Zone Lymphoma, MZL","enrollment":33},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":30},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT07460362","phase":"PHASE2","title":"Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-08-11","conditions":"MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)","enrollment":43},{"nctId":"NCT02446457","phase":"PHASE2","title":"Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma","enrollment":53},{"nctId":"NCT02629809","phase":"PHASE2","title":"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-18","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":81},{"nctId":"NCT06475495","phase":"PHASE1, PHASE2","title":"Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-12-04","conditions":"Rheumatoid Arthritis","enrollment":13},{"nctId":"NCT02339922","phase":"PHASE2","title":"Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2016-05-19","conditions":"Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma","enrollment":33},{"nctId":"NCT04802590","phase":"PHASE2","title":"Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2022-01-24","conditions":"Mantle Cell Lymphoma","enrollment":194},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT04231877","phase":"PHASE1","title":"Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-10-27","conditions":"Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":56},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT05660967","phase":"PHASE2","title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-03-06","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":111},{"nctId":"NCT05950165","phase":"PHASE1, PHASE2","title":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Cho Pharma Inc.","startDate":"2020-01-15","conditions":"Non-Hodgkin Lymphoma","enrollment":37},{"nctId":"NCT06209619","phase":"PHASE1","title":"CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Nathan Denlinger","startDate":"2024-01-29","conditions":"B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent","enrollment":18},{"nctId":"NCT07439263","phase":"PHASE1","title":"Single Ascending Dose Study of HB2198 in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Hinge Bio","startDate":"2026-02-23","conditions":"Healthy Volunteer","enrollment":32},{"nctId":"NCT01473628","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-05-20","conditions":"Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Follicular Lymphoma","enrollment":81},{"nctId":"NCT06433765","phase":"","title":"A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)","status":"RECRUITING","sponsor":"TG Therapeutics, Inc.","startDate":"2024-06-01","conditions":"Multiple Sclerosis","enrollment":728},{"nctId":"NCT07432022","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2026-03-01","conditions":"Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07","enrollment":115},{"nctId":"NCT04169737","phase":"PHASE2","title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":168},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT06536049","phase":"PHASE1, PHASE2","title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Yazeed Sawalha","startDate":"2025-04-02","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":38},{"nctId":"NCT05336812","phase":"PHASE2","title":"Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-09-13","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":52},{"nctId":"NCT01880567","phase":"PHASE2","title":"Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-07-15","conditions":"CCND1 Positive, CCND2 Positive, CCND3 Positive","enrollment":113},{"nctId":"NCT04745949","phase":"PHASE2","title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-10","conditions":"Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":31},{"nctId":"NCT03198026","phase":"PHASE2","title":"Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-02-20","conditions":"Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma","enrollment":30},{"nctId":"NCT05861050","phase":"PHASE1, PHASE2","title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-10","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":50},{"nctId":"NCT06563596","phase":"PHASE2","title":"Epco, Zanu, Ritux for R/R FL or MZL","status":"RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2025-01-21","conditions":"Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT06723457","phase":"PHASE2","title":"Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2025-07-25","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":34},{"nctId":"NCT02846623","phase":"PHASE2","title":"Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-01-31","conditions":"Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia","enrollment":50},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT06644183","phase":"PHASE1, PHASE2","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"Jennifer R. Brown, MD, PhD","startDate":"2025-03-19","conditions":"Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia","enrollment":64},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT05786040","phase":"PHASE2","title":"Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder","status":"RECRUITING","sponsor":"Timothy Voorhees","startDate":"2023-03-23","conditions":"Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder","enrollment":28},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia","enrollment":20},{"nctId":"NCT04883437","phase":"PHASE2","title":"Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-09-03","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":49},{"nctId":"NCT03516617","phase":"PHASE2","title":"Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-09-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":120},{"nctId":"NCT03749018","phase":"PHASE2","title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bond, MD","startDate":"2019-01-02","conditions":"Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT04850495","phase":"PHASE1","title":"Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"Yazeed Sawalha","startDate":"2021-11-16","conditions":"Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":38},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":904},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT05633615","phase":"PHASE2","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-06-12","conditions":"Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":396},{"nctId":"NCT02651662","phase":"PHASE1","title":"A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-11","conditions":"Relapsed/Refractory Aggressive B-Cell Lymphoma","enrollment":105},{"nctId":"NCT04285268","phase":"PHASE2","title":"Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-05-06","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT06357676","phase":"PHASE1, PHASE2","title":"Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-05-29","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT04419519","phase":"PHASE2","title":"Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-05-13","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":81},{"nctId":"NCT01959698","phase":"PHASE1","title":"Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2014-04-17","conditions":"CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":29},{"nctId":"NCT06834373","phase":"PHASE2","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-02","conditions":"Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma","enrollment":41},{"nctId":"NCT04510220","phase":"PHASE3","title":"9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-21","conditions":"Relapsing Multiple Sclerosis","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1468,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rituximab or biosimilar"],"phase":"phase_3","status":"active","brandName":"Anti-CD20 antibody","genericName":"Anti-CD20 antibody","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-CD20 antibodies bind to CD20 antigen on B cells, leading to B cell depletion through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Autoimmune diseases (e.g., rheumatoid arthritis, pemphigus vulgaris).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}